Patents Assigned to Ortho-McNeil Pharmaceutical, Inc.
  • Anticonvulsant derivatives useful for preventing the development of type II diabetes mellitus and syndrome X
    Patent number: 7109174
    Abstract: Anticonvulsant derivatives useful for preventing the development of Type II diabetes mellitus and Syndrome X are disclosed.
    Type: Grant
    Filed: May 11, 2004
    Date of Patent: September 19, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Carlos Plata-Salaman, Jeffrey Crooke
  • Heterocyclic amide derivatives for the treatment of diabetes and other diseases
    Patent number: 7102000
    Abstract: The present invention relates to certain substituted heterocycles of Formula (200), wherein B, H, I, J and K together with the Ar5 form a ring containing at least one amide residue, and W, X, Y and Z together form a 2,4-thiazolidinedione, 2-thioxo-thiazolidine-4-one, 2,4-imidazolidinedione or 2-thioxo-imidazolidine-4-one residue; or a pharmaceutically acceptable salt thereof. The compounds are useful in the treatment of diseases such as type 2 diabetes, and related disorders of lipid and carbohydrate metabolism, including atherosclerosis. The compounds are also useful for treating diseases of uncontrolled proliferation, such as cancers in general, including breast cancer.
    Type: Grant
    Filed: March 6, 2003
    Date of Patent: September 5, 2006
    Assignees: Incyte San Diego Inc., Ortho McNeil Pharmaceutical Inc.
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien A. Al-Shamma, Andrea Fanjul Giachino, Karine Jakubowicz-Jaillardon, Jianhua Guo, Mohamed Boudjelal, James W. Zapf
  • Anticonvulsant derivative salts
    Patent number: 7098188
    Abstract: The invention relates to novel pharmaceutically acceptable salts of anticonvulsant derivatives, processes for preparation of and pharmaceutical compositions containing said salts, useful in the treatment of epilepsy.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: August 29, 2006
    Assignee: Ortho-McNeil Pharmaceutical., Inc.
    Inventors: Ahmed Abdel-Magid, Cynthia Maryanoff
  • Human vanilloid receptor VR3 protein
    Patent number: 7094877
    Abstract: DNA encoding human VR1 receptor has been cloned and characterized. The recombinant protein is capable of forming biologically active protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.
    Type: Grant
    Filed: March 4, 2002
    Date of Patent: August 22, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Adrienne Elizabeth Dubin, Arne Huvar, Charles A. Glass, Mark G. Erlander
  • Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
    Patent number: 7087643
    Abstract: This invention is directed to a method for preventing or treating neuropathic pain and cluster and migraine headache-associated pain comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I): wherein phenyl is substituted at X with one to five halogen atoms independently selected from the group consisting of fluorine, chlorine, bromine and iodine; and; R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen and C1–C4 alkyl; wherein C1–C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of hydrogen, halogen, C1–C4 alkyl, C1–C4 alkoxy, amino, nitro and cyano).
    Type: Grant
    Filed: June 16, 2004
    Date of Patent: August 8, 2006
    Assignee: Ortho-McNeil Pharmaceutical Inc.
    Inventors: Ellen C. Codd, Carlos R. Plata-Salaman, Boyu Zhao
  • Phenyl-substituted imidazopyridines
    Patent number: 7087757
    Abstract: The invention features pharmaceutically-active imidazopyridines and derivatives that are substituted with phenyl, methods of making them, and methods of using them.
    Type: Grant
    Filed: October 7, 2004
    Date of Patent: August 8, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: J. Guy Breitenbucher, Nicholas I. Carruthers, Xiaobing Li, Laura C. McAtee, Chandravadan R. Shah, Ronald L. Wolin
  • N-heterocyclyl hydrazides as neurotrophic agents
    Patent number: 7087628
    Abstract: This invention relates to a series of N-heterocyclyl hydrazides of Formula I, and pharmaceutical compositions containing them. The compounds of the invention have neurotrophic activity and are useful in the treatment and prevention of neuronal disorders such as Parkinson's disease, Alzheimer's disease, stroke, multiple sclerosis, amyotrophic lateral sclerosis diabetic neuropathy and Bell's palsy.
    Type: Grant
    Filed: October 4, 2002
    Date of Patent: August 8, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Zhihua Sui, Mark Macielag, James Lanter
  • Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
    Patent number: 7081460
    Abstract: The invention is directed to novel quinazoline and quinazoline-like derivatives of Formula (I): useful as integrin antagonists and methods for the treatment of integrin-mediated disorders.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: July 25, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: William J. Hoekstra, Edward C. Lawson, Michael J. Costanzo
  • Carbamate compounds for use in preventing or treating anxiety disorders
    Patent number: 7078436
    Abstract: This invention is directed to a method for preventing or treating anxiety disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II): wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: July 18, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Carlos R. Plata-Salaman, Boyu Zhao, Roy E. Twyman
  • Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors
    Patent number: 7074779
    Abstract: The present invention is directed to novel estrieno[3,2-b]/[3,4-c]pyrrole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and diseases mediated by an estrogen receptor.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: July 11, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Zhihua Sui, Xuqing Zhang
  • N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases
    Patent number: 7071218
    Abstract: The present invention relates to certain compounds of Formula (I) which can be useful in the treatment of diseases, such as, cancer, metabolic disorders, Type 2 Diabetes, dyslipidemia and/or hyperchloesterolemia:
    Type: Grant
    Filed: November 15, 2002
    Date of Patent: July 4, 2006
    Assignees: Incyte San Diego Incorporated, Ortho McNeil Pharmaceutical Inc.
    Inventors: Magnus Pfahl, Catherine Tachdjian, Lyle W. Spruce, Hussien A. Al-Shamma, Mohamed Boudjelal, Andrea N. Fanjul, Torsten R. Wiemann, David P. M. Pleynet
  • Method to detect modulators of VEGF kinase domain
    Patent number: 7070938
    Abstract: The present invention relates to assays for the detection of compounds with pharmacological activity, particularly for the detection of modulators of rat vascular endothelial growth factor receptor (rat VEGF-R2) kinase domain.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: July 4, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Dana L. Johnson, Stuart L. Emanuel
  • Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
    Patent number: 7071195
    Abstract: Amine and amide derivatives of the formula: which are ligands for the neuropeptide Y Y5 (NPY5) receptor, methods of preparation and pharmaceutical compositions containing amines and amides of formula A as the active ingredient are described. The amines and amides of formula A are useful in the treatment of disorders and diseases associated with NPY receptor subtype Y5.
    Type: Grant
    Filed: February 7, 2002
    Date of Patent: July 4, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Scott L. Dax, James McNally, Mark Youngman
  • Human serine protease D-G polypeptide
    Patent number: 7070977
    Abstract: Polypeptides corresponding to a novel S1 serine protease family member, termed protease D-G, and nucleic acids encoding them are described. The materials may be used, for example, in screening assays to identify protease D-G modulators and in methods for diagnosing or treating conditions associated with aberrant protease D-G activity.
    Type: Grant
    Filed: March 17, 2004
    Date of Patent: July 4, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Andrew L. Darrow, Jenson (Jian-Shen) Qi, Patricia Andrade-Gordon
  • Non-imidazole aryloxypiperidines
    Patent number: 7071191
    Abstract: Substituted non-imidazole aryloxypiperidine compounds, compositions containing them, and methods of making and using them to treat or prevent histamine-mediated conditions.
    Type: Grant
    Filed: August 6, 2001
    Date of Patent: July 4, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Richard Apodaca, Nicholas I. Carruthers, Curt A. Dvorak, Chandravadan R. Shah, Wei Xiao
  • Process for the preparation of tetrasubstituted imidazole derivatives and novel crystalline structures thereof
    Patent number: 7067671
    Abstract: The present invention relates to a process for preparing tetrasubstituted imidazole derivatives of the general formula (I) wherein R1, R2, R3 and R4 are as defined in the specification below. The present invention further relates to a process for preparing the compound of formula (II) and novel crystalline structures of the compound of formula (II).
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: June 27, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Hua Zhong, Silke Dubberke, Stefan Müller, Armin Rossler, Thomas W. Schultz, Daniel J. Korey, Thomas Otten, Donald G. Walker, Ahmed Abdel-Magid
  • Human voltage gated sodium channel ?1A subunit and methods of use
    Patent number: 7063953
    Abstract: DNAs encoding human voltage gated sodium channel ?1A subunit have been cloned and characterized. The recombinant protein is capable of forming biologically active protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: June 20, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Ning Qin, Ellen Codd, Michael D'Andrea
  • 1,2,4-thiadiazole derivatives as melanocortin receptor modulators
    Patent number: 7049331
    Abstract: The present invention is directed to novel 1,2,4-thiadiazole derivatives useful as agonists or antagonists of the melanocortin receptor. More particularly, the compounds of the present invention are useful for the treatment of metabolic, CNS and dermatological disorders such as obesity, impaired oral glucose tolerance, elevated blood glucose levels, type II diabetes, Syndrome X, diabetic retinopathy, spinal cord injury, nerve injury, acute neurodegenerative disorders, chronic neurodegenerative disorders, plexopathies, male erectile dysfunction, dry eyes, acne, dry skin, aged skin, seborrheic dermatitis, rosacea, excessive ear wax, meibomian gland disorder, pseudofolliculitis, yeast infections, dandruff, hidradenitis suppurativa, ocular rosacea and eccrine gland disorder.
    Type: Grant
    Filed: November 4, 2002
    Date of Patent: May 23, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Magdalena Eisinger, Louis J. Fitzpatrick, Daniel H. Lee, Kevin Pan, Carlos Plata-Salaman, Allen B. Reitz, Virginia L. Smith-Swintosky, Boyu Zhao
  • Neuroblastoma cell lines expressing the ?2? subunit of calcium channels and methods therefore
    Patent number: 7049084
    Abstract: The present invention provides methods for identifying test substances that bind to the ?2? subunit of a calcium channel.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: May 23, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Sui-Po Zhang, Susan K. Yagel, Ellen E. Codd
  • Composition comprising a tramadol material and acetaminophen and its use
    Patent number: RE39221
    Abstract: This invention relates to a composition comprising a tramadol material and acetaminophen, and its use. As used herein tramadol refers to various forms of tramadol. The compositions are pharmacologically useful in treating pain and tussive conditions. The compositions are also subject to less opioid side-effects such as abuse liability, tolerance, constipation and respiratory depression. Furthermore, where the components of the compositions are within certain ratios the pharmacological effects of the compositions are superadditive (synergistic).
    Type: Grant
    Filed: January 20, 2004
    Date of Patent: August 1, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Robert B. Raffa, Jeffrey L. Vaught